Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2022

View Archived Issues

GTX-0196 shows complete tumor growth suppression in models of AML

Storm Therapeutics divulges new METTL3 inhibitors

New MRGPRX2 antagonists identified at GlaxoSmithKline

PRISM BioLab discovers Notch signaling inhibitors

Leukos Biotech patents serotonin 5-HT1B receptor antagonists

Ingenew BioPharma synthesizes new IL-1beta, IL-6 and TNF-alpha release inhibitors

In times of need, fat cells take on immune functions

Janssen describes discovery of improved Mcl-1 inhibitor JNJ-4355

MJFF grant supports Asceneuron's preclinical evaluation of ASN-51 for Parkinson's disease

Dianthus closes series A financing to support development of antibody complement therapeutics

CRD-1600 demonstrates robust immune modulatory properties in vitro and in vivo

Studies show KRAS G12C inhibitor APG-1842 is potent, bioavailable and highly selective

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...